New strategy aims to stop hospitalized patients from crashing
NCT ID NCT07334379
Summary
This study is testing if measuring a specific inflammation marker (IL-6) in the blood can help doctors identify which hospitalized patients with severe breathing problems are at risk of getting much worse. If the marker is high, patients will receive either standard care alone, or standard care plus an anti-inflammatory drug (tocilizumab or dexamethasone) to try to prevent organ failure or death. The main goal is to see if this treatment strategy is practical to carry out in a hospital setting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE HYPOXEMIC RESPIRATORY FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.